GlassScriptPhysician profile
Michael S Gebetsberger
NPI 1851378350
$13,369.98
in general payments reported to CMS, 2019-2025
52 companies · $3,513 in 2025
The $3,513 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,309 · 2020: $445 · 2022: $946 · 2023: $2,218 · 2024: $2,939 · 2025: $3,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,631 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,630.68 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,591.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,305.01 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,245.86 | 2019-2025 | |
| Abbvie INC. | $1,103.86 | 2022-2025 | |
| Amgen INC. | $905.06 | 2019-2025 | Krystexxa, Evenity, Prolia |
| Lilly USA, LLC | $764.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $690.39 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $634.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.74 | 2019-2025 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $375.50 | 2019-2025 | Trintellix |
| Abbott Laboratories | $374.90 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.72 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.72 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $306.29 | 2019-2024 | Xarelto |
| Axsome Therapeutics, INC. | $256.10 | 2022-2025 | Auvelity |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gebetsberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.